Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 1, 2016, Pages 226-234

  Lai, Chung Chih ^a   Liu, Wen Chun ^b   Fang, Chi Tai ^b,c   Yang, Jyh Yuan ^d   Chang, Lan Hsin ^b   Wu, Pei Ying ^b   Luo, Yu Zhen ^b   Chang, Shu Fang ^e   Su, Yi Ching ^b   Chang, Sui Yuan ^b,e   Hung, Chien Ching ^b,f  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d CENTER FOR DISEASE CONTROL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COUNSELING; FEMALE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; ORAL SEX; SEXUAL PRACTICE; TAIWAN; TRANSMITTED DRUG RESISTANCE; VIRUS STRAIN; VOLUNTARY COUNSELLING AND TESTING; VOLUNTARY PROGRAM; ADULT; DISEASE TRANSMISSION; DRUG EFFECTS; GENETICS; GENOTYPE; GENOTYPING TECHNIQUE; HIV INFECTIONS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; PREVALENCE; TRANSMISSION; VIROLOGY; YOUNG ADULT;

ADULT; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PREVALENCE; TAIWAN; YOUNG ADULT;

EID: 84960146295     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv284     Document Type: Article

References (36)

1. HIV/AIDS Programme. WHO HIV Drug Resistance Report 2012. http:// apps.who.int/iris/bitstream/10665/75183/1/9789241503938_eng.pdf.
2. Hamers RL, Wallis CL, Kityo C et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11: 750-9.
3. Hamers RL, Schuurman R, Sigaloff KCE et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012; 12: 307-17.
4. Wittkop L, Gunthard HF, deWolf F et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363-71.
5. Lai CC, Hung CC, Chen MYet al. Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan. J Antimicrob Chemother 2012; 67: 1254-60.
6. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380: 1250-8.
7. Rhee SY, Blanco JL, Jordan MR et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level metaanalysis. PLoS Med 2015; 12: e1001810.
8. Resistance UKCGoHD, Dolling D, Sabin C et al. Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ 2012; 345: e5253.
9. Baxter JD, Dunn D, White E et al. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 Suppl 1: 77-87.
10. Sohn AH, Srikantiah P, Sungkanuparph S, Zhang F. Transmitted HIV drug resistance in Asia. Curr Opin HIV AIDS 2013; 8: 27-33.
11. Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012; 14: 17-27.
12. Pham QD, Wilson DP, Law MG et al. Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS 2014; 28: 2751-62.
13. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. https:// aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
14. Stekler JD, McKernan J, Milne R et al. Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther 2015; 20: 77-80.
15. Descamps D, Assoumou L, Chaix MLet al. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. J Antimicrob Chemother 2013; 68: 2626-31.
16. Saladini F, Meini G, Bianco C et al. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naive and pretreated patients. Clin Microbiol Infect 2012; 18: E428-30.
17. Grobler JA, Hazuda DJ. Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences. Curr Opin Virol 2014; 8: 98-103.
18. Hu Z, Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 2010; 55: 148-55.
19. Jahanbakhsh F, Hattori J, Matsuda M et al. Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011. PLoS One 2013; 8: e61864.
20. Chang SY, Chen MY, Lee CN et al. Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan. J Antimicrob Chemother 2008; 61: 689-93.
21. Kiertiburanakul S, Chaiwarith R, Sirivichayakul S et al. Comparisons of primary HIV-1 drug resistance between recent and chronic HIV-1 infection within a sub-regional cohort of Asian patients. PLoS One 2013; 8: e62057.
22. Wu H, Wu PY, Li SY et al. Maximising the potential of voluntary counselling and testing for HIV: sexually transmitted infections and HIV epidemiology in a population testing for HIV and its implications for practice. Sex Transm Infect 2012; 88: 612-6.
23. Truong HM, Kellogg TA, McFarland W et al. Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. PLoS One 2011; 6: e25281.
24. Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill 2008; 13: pii=18966.
25. Kao CF, Chang SY, Hsia KT et al. Surveillance of HIV type 1 recent infection and molecular epidemiology among different risk behaviors between and 2009 after the HIV type 1 CRF07_BC outbreak in Taiwan. AIDS Res Hum Retroviruses 2011; 27: 745-9.
26. Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4: e4724.
27. To SW, Chen JH,Wong KH et al. Performance comparison of an in-house integrase genotyping assay versus the ViroSeq Integra48, and studyof HIV-1 integrase polymorphisms in Hong Kong. J Clin Virol 2013; 58: 299-302.
28. Yanik EL, Napravnik S, Hurt CB et al. Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr 2012; 61: 258-62.
29. Weng YW, Tsai HC, Lee SS et al. Prevalence and associated factors for HIV-1 transmitted drug resistance in voluntary clients for counseling and testing in Southern Taiwan. J Microbiol Immunol Infect 2014; doi:10.1016/ j.jmii.2014.08.002.
30. Sun HY, Cheng CY, Lee NY et al. Seroprevalence of hepatitis B virus among adults at high risk for HIV transmission two decades after implementation of nationwide hepatitis B virus vaccination program in Taiwan. PLoS One 2014; 9: e90194.
31. Fujisaki S, Yokomaku Y, Shiino Tet al. Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. J Clin Microbiol 2011; 49: 1017-24.
32. Fransen S, Gupta S, Danovich R et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009; 83: 11440-6.
33. Jones GS, Yu F, Zeynalzadegan A et al. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 2009; 53: 1194-203.
34. Malet I, Delelis O, Valantin MA et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008; 52: 1351-8.
35. Blanco JL, Varghese V, Rhee SY et al. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011; 203: 1204-14.
36. Wensing AM, Calvez V, Gunthard HF et al. 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med 2014; 22: 642-50.